NovaBridge Biosciences (NBP) Status Update summary

Clinical and market overview

• Givastomig, a bispecific 18.2/4-1BB antibody, is being developed as an add-on to standard IO chemo for frontline metastatic gastric cancer, addressing a $12B market by 2030.

• Gastric cancer remains a significant unmet need, ranking fifth globally in incidence and mortality.

• Givastomig offers the broadest claudin 18.2 patient coverage among active clinical studies, with eligibility at 1% expression.

• Financial position is strong, with $168M on the balance sheet, supporting upcoming clinical milestones.

Differentiation and mechanism of action

• Givastomig demonstrates high-affinity binding to claudin 18.2 and conditional 4-1BB activation, minimizing systemic toxicity.

• The asset is engineered to eliminate ADCC and CDC, reducing unintended immune activation.

• Activation of T cells occurs only in the tumor microenvironment, limiting off-target effects.

Monotherapy and combination data

• Monotherapy in heavily pretreated patients showed an 18% ORR with a favorable safety profile and no dose-limiting toxicities.

• Compared to other 18.2 assets, Givastomig has the lowest expression threshold and higher ORR than zolbituximab.

• Grade 3+ adverse events were lower for Givastomig (33%) than ADCs and T cell engagers (nearly 60%).